Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-01-03
1998-08-11
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514532, 514539, 549510, 549553, 560 39, 424450, 424455, A61K 31335, C07D30310
Patent
active
057927928
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/EP95/01341, filed Apr. 13, 1995.
The invention relates to new pharmacologically active compounds, which have the power to influence tubulin polymerization or tubulin depolymerization.
A number of natural mitotic poisons are used as anti-tumor agents or are undergoing clinical trials. Various classes of these mitotic poisons exist that exert their cytotoxic effect either by inhibiting the polymerization of microtubuli in a spindle device (e.g., vinca alkaloids, colchicine) or accomplish this by a GTP-independent increase of the polymerization of the tubulin and prevention of the depolymerization of microtubuli (e.g., taxol, taxotere). Owing to previously little-understood physicochemical properties and the characteristics of neoplastic cells, mitotic poisons have a certain selectivity for tumor cells, but there is also significant cytotoxicity with regard to nontransformed cells.
Up until now, vinca alkaloids have had great importance in the combined chemotherapy of myeloid tumors. Taxanes have very recently opened up important applications that were not accessible by previously available cytostatic agents, e.g., ovarian cancers, malignant melanomas. The side-effects of taxanes are comparable to those of other cytostatic agents, however (e.g., loss of hair, sensory neuropathy). Multi-drug-resistant tumor cells, which over-express the P-glycoprotein, are resistant to taxanes. The limited availability of the natural substance taxol also inhibits broader clinical trials.
Natural substances and synthetic pharmaceutical agents that have a spectrum of action unlike that of the previous mitotic poisons were therefore tested. An in vitro experimental arrangement makes it possible to search for substances that do not influence the GTP-dependent polymerization of tubulin, but influence the depolymerization of the microtubuli formed. Substances with such a profile of action should influence the versatile functions of microtubuli in extranuclear cell compartments less strongly than the dynamic of the spindle device during mitosis (metaphase, anaphase). Logically, such compounds should have fewer side-effects in vivo than taxanes or vinca alkaloids.
Tubulin is an essential component of the mitotic spindle. It is used, i.a., to preserve the cell shape, to transport organelles inside the cell, and to influence cell mobility.
Up until now, taxanes has represented the only known structural class that is able to accelerate the polymerization of tubulin (mainly in the G2 phase), as well as to stabilize the microtubuli polymers formed. This mechanism is clearly distinguishable from those that have other structural classes which also influence the phase-specific cell division. Thus, for example, substances from the group of vinca alkaloids (e.g., vincristines and vinblastines) but also colchicine inhibit the polymerization of the tubulin dimers in the M phase.
It has now been found that compounds of formula I that are comparatively simple to produce are able to inhibit the depolymerization of microtubuli without increasing the formation of microtubuli in a GTP-independent manner. Moreover, compounds with a completely new profile of action that are able to accelerate the depolymerization of microtubuli were identified. On the basis of these properties, the compounds of formula I represent valuable pharmaceutical agents that are basically able to supplement or replace taxanes, which are difficult to synthesize and which are still not available in sufficient quantity, such as, e.g., taxol and Taxotere.RTM., in the treatment of malignant tumors (EP-A 253739).
The new borneol derivatives are characterized by general formula I ##STR3## in which R.sup.1 means C(O)--CH(OR.sup.6)--CH(NHR.sup.7)--R.sup.8, alkoxy, --OC(O)R.sup.9a, --OSO.sub.2 R.sup.9a, --OP(O)(OH).sub.2, NHR.sup.9a, NR.sup.9a R.sup.9b, --OSO.sub.2 R.sup.9b, --OP(O)(OH).sub.2, or --OR.sup.11a, --OR.sup.11b, or --C(O)NHR.sup.9d, --C(O)NR.sup.9d R.sup.9e, ##STR4## R.sup.8 means aryl, R.sup.9a-e, R.sup.12 are the same or different and mean C.s
REFERENCES:
patent: 5248796 (1993-09-01), Chen et al.
patent: 5405972 (1995-04-01), Holton et al.
Wender, P.A. et al, `A New and Practical Approach to the Synthesis of Taxol and Taxol Analogues: The Pinene Path` J. Am. Chem. Soc. 1992, 114, pp. 5878-5879.
Blechert Siegfried
Graf Hermann
Klar Ulrich
Neef Gunter
Dahlen Garth M.
Ivy C. Warren
Schering Aktiengesellschaft
LandOfFree
Borenol derivatives, process for their production and their phar does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Borenol derivatives, process for their production and their phar, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Borenol derivatives, process for their production and their phar will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-389426